Vistagen Therapeutics Income Statement (2010-2025) | VTGN

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	0.44M	0.35M	0.36M	0.36M	0.04M	0.31M	0.89M	0.18M	0.18M	0.20M	0.30M	0.41M	0.16M	0.08M	0.18M	0.23M	-0.01M	0.24M	0.26M	0.30M
Operating items
Research & Development (Quarter)	4.89M	5.46M	9.94M	7.78M	12.23M	15.29M	12.89M	6.85M	9.34M	4.20M	3.85M	4.54M	7.44M	7.65M	10.21M	11.30M	10.21M	11.68M	15.91M	14.22M
Selling, General & Administrative (Quarter)	1.77M	2.64M	3.22M	3.12M	4.50M	4.79M	3.70M	3.09M	3.08M	2.98M	3.21M	3.76M		4.57M	4.20M	4.05M	4.27M	4.37M	4.40M	5.63M
Other Operating Expenses (Quarter)													4.12M
Operating Expenses (Quarter)	6.66M	8.10M	13.16M	10.90M	16.73M	20.08M	16.60M	9.95M	12.41M	7.17M	7.06M	8.29M	11.56M	12.21M	14.41M	15.35M	14.48M	16.05M	20.31M	19.85M
Operating Income (Quarter)	-6.22M	-7.75M	-12.80M	-10.54M	-16.69M	-19.77M	-17.49M	-9.77M	-12.24M	-7.00M	-6.78M	-7.88M	-11.36M	-12.13M	-14.23M	-15.12M	-14.49M	-15.80M	-20.05M	-19.55M
EBIT (Quarter)	-6.22M	-7.75M	-12.80M	-10.54M	-16.69M	-19.77M	-17.49M	-9.77M	-12.24M	-7.00M	-6.78M	-7.88M	-11.36M	-12.13M	-14.23M	-15.12M	-14.49M	-15.80M	-20.05M	-19.55M
Non-operating items
Interest & Investment Income (Quarter)										0.10M	0.19M	1.53M	1.53M	1.40M	1.27M	1.03M	0.85M	0.71M	0.63M	0.65M
Other Non Operating Income (Quarter)																	0.01M	-0.00M	0.01M
Non Operating Income (Quarter)																		-0.00M	0.01M
Net income details
EBT (Quarter)	-6.21M	-7.74M	-12.79M	-10.53M	-16.69M	-19.77M	-17.48M	-9.76M	-12.23M	-6.90M	-6.59M	-6.35M	-9.52M	-10.73M	-12.95M	-14.09M	-13.63M	-15.10M	-19.42M	-18.90M
Tax Provisions (Quarter)		0.00M				0.01M			0.00M	0.00M			0.00M		0.01M
Profit After Tax (Quarter)	-6.21M	-7.75M	-12.79M	-10.53M	-16.69M	-19.78M	-17.48M	-9.76M	-12.23M	-6.90M	-6.59M	-6.35M	-9.52M	-10.73M	-12.96M	-14.09M	-13.63M	-15.10M	-19.42M	-18.90M
Income from Continuing Operations (Quarter)	-6.21M	-7.75M	-12.79M	-10.53M	-16.69M	-19.78M	-17.48M	-9.76M	-12.23M	-6.90M	-6.59M	-6.35M	-9.52M	-10.73M	-12.96M	-14.09M	-13.63M	-15.10M	-19.42M	-18.90M
Consolidated Net Income (Quarter)	-6.21M	-7.75M	-12.79M	-10.53M	-16.69M	-19.78M	-17.48M	-9.76M	-12.23M	-6.90M	-6.59M	-6.35M	-9.52M	-10.73M	-12.96M	-14.09M	-13.63M	-15.10M	-19.42M	-18.90M
Income towards Parent Company (Quarter)	-6.21M	-7.75M	-12.79M	-10.53M	-16.69M	-19.78M	-17.48M	-9.76M	-12.23M	-6.90M	-6.59M	-6.35M	-9.52M	-10.73M	-12.96M	-14.09M	-13.63M	-15.10M	-19.42M	-18.90M
Preferred Dividend Payments (Quarter)	0.35M	0.36M	0.38M	0.21M
Net Income towards Common Stockholders (Quarter)	-29.56M	-8.11M	-13.17M	-10.74M	-16.69M	-19.78M	-17.48M	-9.76M	-12.23M	-6.90M	-6.59M	-6.35M	-9.52M	-10.73M	-12.96M	-14.09M	-13.63M	-15.10M	-19.42M	-18.90M
Additional items
EPS (Basic) (Quarter)	-0.20	-1.28	-2.04	-1.59	-2.42	-2.87	-2.54	-1.42	-1.71	-0.94	-0.66	-0.22	-0.25	-0.35	-0.42	-0.46	-0.44	-0.47	-0.54	-0.45
EPS (Weighted Average and Diluted) (Quarter)									-1.76	-0.94	-0.66	-0.22	-0.25	-0.35	-0.42	-0.46	-0.44	-0.47	-0.54	-0.45
Shares Outstanding (Weighted Average) (Quarter)	86.13M	6.33M	6.44M	6.74M	6.60M	6.89M	9.28M	2.40M	6.96M	7.34M	8.72M	29.39M	19.35M	11.27M	30.62M	30.65M	30.88M	9.29M	9.29M	42.23M
Shares Outstanding (Diluted Average) (Quarter)									6.96M	7.34M	10.04M	29.39M	19.35M	30.60M	30.62M	30.71M	30.88M	31.93M	35.75M	42.23M
EBITDA (Quarter)	-6.22M	-7.75M	-12.80M	-10.54M	-16.69M	-19.77M	-17.49M	-9.77M	-12.24M	-6.90M	-6.59M	-6.35M	-9.52M	-10.73M	-12.94M	-14.10M	-13.64M	-15.10M	-19.40M	-18.90M
Interest Expenses (Quarter)
Shares Outstanding (Quarter)	6.03M	2.32M	1.13M	206.64M	6.89M	6.90M	6.90M	6.90M	7.32M	7.88M	12.02M	27.03M	27.03M	27.06M	27.06M	28.32M	29.00M	29.29M	38.90M	39.62M
Tax Rate (Quarter)		-0.04				-0.03			-0.01	-0.04			-0.01		-0.05

Research Tools

Vistagen Therapeutics Income Statement (2010-2025) | VTGN

Create an account

Sign In

Reset Password